fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Semaglutide for obesity treatment

Written by | 13 May 2023

Alex Miras is Professor of Endocrinology at the University of Ulster, UK and is an expert in obesity management and research. In 2021 a trial of semaglutide for… read more.

Could semaglutide prevent cardiometabolic disease?

Written by | 12 May 2023

Professor Alex Miras, consultant endocrinologist at the University of Ulster, takes the view that obesity is a disease. He explains why this is and how the SELECT trial… read more.

Do I need semaglutide and how can I get it?

Written by | 11 May 2023

Semaglutide works well on its own as obesity treatment but it works even better with the support and guidance of a multi-disciplinary weight-management team, according to Alex Miras,… read more.

NICE recommends semaglutide for obesity

Written by | 10 May 2023

In March 2023 the National Institute for Health and Care Excellence (NICE) published Technology Appraisal Guidance for semaglutide for obesity. Professor Alex Miras explains the guidance and its… read more.

Semaglutide – a game-changer in obesity management

Written by | 9 May 2023

Alex Miras is Professor of Endocrinology at the University of Ulster, UK and is an expert in obesity management and research. In 2021 a trial of semaglutide for… read more.

Obesity drug helps teens lose weight, study finds

Written by | 7 Nov 2022

A drug called semaglutide, which is approved for adults with obesity or overweight, also helps adolescents shed pounds and have healthier hearts, according to a new study published… read more.

First medical guideline recommends new prescription medications for weight loss

Written by | 24 Oct 2022

Diet and exercise fail for most adults who try to lose weight in the long-term. Today the American Gastroenterological Association (AGA) released new evidence-based guidelines strongly recommending that these patients… read more.

Study shows game-changing obesity drug more than halves risk of type 2 diabetes

Written by | 20 Sep 2022

The risk of type 2 diabetes (T2D) is more than halved by weekly injections of new obesity drug semaglutide, according to new research being presented at the annual… read more.

Semaglutide leads to significant weight loss in Type 2 diabetes patients

Written by | 17 May 2021

Article by Bruce Sylvester. Patients diagnosed with type 2 diabetes and treated with weekly semaglutide have achieved an average weight loss of almost 10kg, researchers reported on March… read more.

Semaglutide reduces excess body fat in people with obesity

Written by | 31 Mar 2021

In adults with obesity or overweight, weekly treatment with the glucagon-like peptide 1 (GLP1) receptor agonist semaglutide leads to reduced excess body fat and increased lean body mass,… read more.

Semaglutide cuts body weight in at-risk obese patients

Written by | 18 Mar 2021

Article by Bruce Sylvesyter. In tandem with lifestyle management, once-weekly semaglutide therapy has enabled obese, non-diabetic patients to lose a significant amount of weight, researchers reported on Feb…. read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.